Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 13, 2025
Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Xi'an Guokang Ruijin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Casi Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela® In China
Details : Under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., will continue to be the sole distributor for the sale of EVOMELA® (melphalan) for Injection in China.
Product Name : Evomela
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
March 04, 2022
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Xi'an Guokang Ruijin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uveal Melanoma.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 26, 2021
Lead Product(s) : Daratumumab,Bortezomib,Melphalan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DARZALEX® SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in administration-related reactions compared to intravenous DARZALEX® (daratumumab).
Product Name : Darzalex Faspro
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 04, 2020
Lead Product(s) : Daratumumab,Bortezomib,Melphalan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 02, 2020
Delcath Systems Prices $22M Public Offering
Details : Delcath intends to use the net proceeds of the offering for working capital and general corporate purposes including the continued development of Melphalan/HDS.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Undisclosed
May 01, 2020
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Myriad genetics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 04, 2019
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Myriad genetics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Mundipharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Bendamustine and Melphalan in Myeloma
Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
June 14, 2017
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Mundipharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Bile Duct Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 22, 2017
Lead Product(s) : Melphalan
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
